Using genetic testing to improve pain management in cancer patients
C-PAIN: Catalyzing Pharmacogenomic Analysis for Informing Pain Treatment
This study tests whether genetic testing can help doctors choose the right opioid doses to better manage pain for adults with cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 800 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Chicago Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT06511401 on ClinicalTrials.gov |
What this trial studies
This study evaluates the impact of preemptive pharmacogenomic testing on opioid dosing decisions and pain management in adult cancer patients. Participants will be randomly assigned to receive pharmacogenomic results that may guide their opioid therapy. The goal is to determine if this approach can lead to better pain control and more personalized treatment plans for patients undergoing oncologic care.
Who should consider this trial
Good fit: Ideal candidates are adults receiving ongoing oncology care who are expected to require opioid pain medication in the near future.
Not a fit: Patients currently taking opioids, undergoing palliative radiation, or with certain medical conditions such as chronic kidney disease or active blood cancers may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective pain management strategies tailored to individual genetic profiles.
How similar studies have performed: Other studies have shown promise in using pharmacogenomic approaches for pain management, indicating potential success for this method.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Persons receiving ongoing oncology care at the University of Chicago Medical Center for whom near-future pain opioid pain medication therapy is anticipated * Subjects must be at least 18 years of age. Exclusion Criteria: * Subjects taking an opioid at the time of enrollment, or within the past 30 days * Subjects who are currently undergoing palliative radiation * Subjects who have undergone, or are being actively considered for, bone marrow, liver or kidney transplantation. * Subjects with a history of or active blood cancer (e.g., leukemia). * Chronic kidney disease, as defined by Glomerular filtration rate (GFR) \< 30/mL/min/1.73m2, due to the risk of decreased drug excretion. * Liver dysfunction, as defined by the following laboratory values, due to the risk of decreased drug metabolism: Total bilirubin greater than or equal to1.5 mg/dL, Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) greater than or equal to 2.5 X upper limit of normal\*. (\*Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) \\ greater than or equal to 5 X upper limit of normal if hepatic metastases are present). * Inability to understand and give informed consent to participate in the opinion of the investigator * Subjects who are known to be pregnant at the time of enrollment * Subjects who have previously or are currently enrolled in another institutional pharmacogenomic genotyping study, or are known to have previously undergone pharmacogenomic genotyping for the gene(s) of interest via another commercial or other means.
Where this trial is running
Chicago, Illinois
- University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois, United States (Recruiting)
Study contacts
- Principal investigator: Peter H O'Donnell — University of Chicago
- Study coordinator: Clinical Trials Intake
- Email: cancerclinicaltrials@bsd.uchicago.edu
- Phone: 1-855-702-8222
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.